PHARVARIS
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.
PHARVARIS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2015-01-01
Address:
Zug, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.pharvaris.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
162.29 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Arctoris
Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Core Biogenesis
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
MiNA Therapeutics
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.
OMass Technologies
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Pharvaris
Venrock
Venrock investment in Series C - Pharvaris
venBio Partners
venBio Partners investment in Series C - Pharvaris
General Atlantic
General Atlantic investment in Series C - Pharvaris
Viking Global Investors
Viking Global Investors investment in Series C - Pharvaris
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series C - Pharvaris
Foresite Capital
Foresite Capital investment in Series C - Pharvaris
Venrock
Venrock investment in Series B - Pharvaris
Foresite Capital
Foresite Capital investment in Series B - Pharvaris
Kurma Partners
Kurma Partners investment in Series B - Pharvaris
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-11 | Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer |
Official Site Inspections
http://www.pharvaris.com Semrush global rank: 5.52 M Semrush visits lastest month: 1.54 K
- Host name: cloudproxy10157.sucuri.net
- IP address: 192.124.249.157
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
